[Study on liver targeted valaciclovir polybutylcyanoacrylate nanoparticles].
The valaciclovir polybutylcyanoacrylate nanoparticles (VACA-PBCA-NP) were prepared by emulsion polymerization method. The morphology, size and size distribution, release characteristics in vitro, drug loading, stability and distribution of VACV-PBCA-NP in mice were studied. The results showed that the dav = 104.77 +/- 11.78 nm, drug loading was 11.20%. The release characteristics in vitro was in accord with two-phase kinetics. 74.49% of the VACV were concentrated in liver at 15 min after i.v. VACA-PBCA-NP. The amount of VACV entering hepatocytes was also increased greatly. This research seems to have important value for increasing the anti-hepatitis B virus effect and decreasing toxicity of VACV.
Zhang
Z
Z
School of Pharmacy, West China University of Medical Sciences, Chengdu 610041.
He
Q
Q
D000212:Acyclovir / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D016503:Drug Delivery Systems; D004659:Enbucrilate; D022781:Hepatocytes / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D051379:Mice; D008863:Microspheres; D011897:Random Allocation; D014018:Tissue Distribution; D000077483:Valacyclovir; D014633:Valine / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*
D000998:Antiviral Agents; D004659:Enbucrilate; D014633:Valine; D000077483:Valacyclovir; D000212:Acyclovir